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Dear Colleagues,
Three weeks ago Pamir Atagunduz, the Chief Editor of 
Marmara Medical Journal, talked to me about his plans for 
the Journal in the upcoming years with great excitement 
and enthusiasm. I felt honored when he asked if I would 
be interested in becoming the invited editor for the first of 
the “Special Issue” series of Marmara Medical Journal.  The 
same day I started to plan how to accomplish an oncology 
issue in a very short period of time. When I called Esra 
Saglam, asking for a review due in 3 weeks, not only she 
said yes, but also encouraged me with her great ideas. Here, 
I would especially thank to all of the authors in this issue for 
writing these manuscripts despite their very busy schedule. 
Also, I owe special thanks to Bruce Minsky for his positive 
approach in contributing to our Journal.  
In addition to the current information regarding positive 
interaction between immunotherapy and radiotherapy you 
will find the latest developments on treatment of various 
cancers in this “Special Issue - Oncology “. 
Gastrointestinal tumors are major health concerns 
in our population. In this issue Bruce Minsky prepared 
a comprehensive review about the advances in the 
management of esophageal carcinoma [1]. Faysal Dane 
outlined the importance of HER-2 targeted therapies on 
gastric carcinomas [2]. Zuleyha Akgun and Esra Saglam 
reviewed their recent data and literature on neoadjuvant 
treatment in rectal carcinomas [3]. 
Prostate cancer is also a major concern in the male 
population. Sefik Igdem and Sevil Bavbek summarized the 
recent advances in hypofractionated radiotherapy for local 
and management of castrate-resistant prostate cancer [4,5]. 
Breast cancer is the most frequent cancer in females in 
the world and in Turkey as well. Palbociclib, a selective 
cyclin-dependent kinase-4 (CDK-4) and CDK-6 inhibitor, 
has achieved accelerated approval designation by the United 
States Food and Drug Administration (FDA) for breast 
cancer treatment on February 3rd, 2015 [6]. Palbociclib is 
indicated in combination with letrozole for the treatment 
of postmenopausal women with estrogen receptor positive, 
human epidermal growth factor receptor-2 negative 
advanced breast cancer as initial endocrine-based therapy 
for their metastases. Bilge Aktas summarized these new 
drugs that inhibit CDK [7]. 
Immunotherapy is the rising star of the last few years. 
New data are emerging day after day and you can find these 
latest developments in immunotherapy and radiotherapy 
interaction in the last topic of this issue by Yavuz Anacak, 
Serra Kamer and Fatma Sert [8]. 
As my primary research interest is lung cancer,  I 
cannot end my editorial without outlining FDA approval 
of nivolumab in patients with non-small cell lung cancer 
(NSCLC) on March 4th, 2015 [9]. We all know that lung 
cancer is the leading cause of cancer death in men around the 
world and also in our country. More than 30 percent of NSCLC 
patients have squamous cell histology because of smoking 
addiction. Nivolumab is one of the new immunotherapies 
that blocks programmed death (PD) pathway. It is a PD-1 
inhibitor. CheckMate 017 trial enrolled 272 patients with 
advanced or metastatic squamous NSCLC who progressed 
on or after platinum-based chemotherapy [10, 11]. Patients 
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were randomized to either nivolumab 3mg/kg every 2 weeks 
or docetaxel 75 mg/m2 every 3 weeks (control group). 
Patients who received nivolumab lived median of 3.2 months 
longer than control group (hazard ratio 0.59, 95% CI 0.44-
0.79; p=.00025). Most common side effects of nivolumab 
are reported as fatigue, shortness of breath, musculoskeletal 
pain, loss of appetite, cough, nausea and constipation. Most 
serious ones are immune-mediated side effects involving 
healthy organs, including lung, colon, liver, kidneys, and 
endocrine glands. Results of this trial was shared with FDA 
as soon as they were available before they are presented in a 
congress or published. FDA will re-evaluate the application 
of nivolumab for squamous cell NSCLC on June 22, 2015.
 Nivolumab is the first immunotherapy to be available 
for use in the treatment of lung cancer with promising 
results. Selection of best patients who will respond to 
immunotherapy and best treatment combination is still to 
come. I feel very optimistic again and this time I do not  want 
to say “I have seen this movie before!”. Instead,  I would like 
to tell this story with a happy ending to my fellows in the 
future. 
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